复宏汉霖H药完成首批面向印度市场的供货

Core Viewpoint - The company has successfully delivered the first batch of its self-developed anti-PD-1 monoclonal antibody, H drug (brand name: Hanshuang, international name: Hetronifly), to the Indian market, marking a significant milestone in its product rollout [1] Group 1 - The H drug received approval from the Central Drugs Standard Control Organization (CDSCO) in India in June 2025 for first-line treatment of extensive-stage small cell lung cancer [1] - This approval makes the H drug the first anti-PD-1 monoclonal antibody to be approved for this indication in India [1]